Aim: This study summarized the existing evidence on the outcomes and safety of anti-PD-1s, anti-PD-L1s and anti-CTLA-4s in pediatric patients with melanoma. Materials & methods: MEDLINE® and Embase w
*Values are means (standard deviation). †Continuation was defined as the proportion of patients who remained on the sirolimus treatment. ‡Adherence was defined for each specific time interval as the a